SCHEDULE: Lytton Discloses 1.6% Stake in Cellectar Biosciences

Laurence W. Lytton has disclosed a 1.6% beneficial ownership stake in Cellectar Biosciences, Inc., primarily through warrants.

Summary

• Laurence W. Lytton reported beneficial ownership of 51,391 shares of Cellectar Biosciences, Inc. Common Stock.
• This stake represents 1.6% of the company's outstanding Common Stock.
• The beneficially owned shares consist of warrants to acquire Common Stock.
• The percentage of class is calculated based on 3,192,040 shares of Common Stock outstanding as of August 12, 2025, as reported in the Issuer's Form 10-Q for the quarter ended June 30, 2025.
• This filing is Amendment No. 4 to a Schedule 13G.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply reports an individual's stake.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an individual investor in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that Cellectar Biosciences operates within the biotechnology sector.

Stakeholder Impact

• Minimal direct impact on shareholders, as it's a disclosure of a non-controlling, sub-5% stake by an individual investor.

Key Dates

Keywords

Cellectar Biosciences, CLRB, Laurence W. Lytton, Schedule 13G, Beneficial Ownership, Warrants, Biotechnology, SEC Filing